Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Technology Stocks : SYNSORB (T.SYB)(SYBBF) CURE FOR CANCER? -- Ignore unavailable to you. Want to Upgrade?

To: Jim Oravetz who wrote (109)	5/25/2000 11:48:00 PM
From: Tupulak	Read Replies (1) \| Respond to of 164

I guess this is a win-win situation for both SYB and the people in Ontario. With what is being made public it was a very big screw up by the officials in this town and people are paying for it. This is free publicity and trails. Curtis

To: Jim Oravetz who wrote (109)	6/29/2000 6:54:00 AM
From: Jim Oravetz	Read Replies (1) \| Respond to of 164

(BW)-June 27, 2000--SYNSORB Biotech Inc. ("SYNSORB") (TSE:SYB) (NASDAQ:SYBB), today announced that the Company has received a milestone payment from MDS Sciex ("MDS") (TSE:MDS). This payment was triggered by the issuance of the first of several key patents which will fully consolidate the intellectual property position of SYNSORB's former subsidiary, INH Technologies Incorporated ("INH") in the lucrative field of high throughput screening. SYNSORB sold INH to MDS in March 2000 in a deal that included an up-front payment, milestone payments that could total up to $1 Million, and royalty payments on future sales. "We are very pleased that the issuance of this patent has triggered the first in a series of anticipated milestone payments," said Dr. David Cox, President and CEO of SYNSORB. "These payments represent net 'profit' for SYNSORB shareholders because the up-front cash payment previously received upon signing the agreement has already covered all of SYNSORB's development costs for INH." The US Patent and Trademark Office issued patent number 6,054,047 on April 25, 2000. The patent relates to an apparatus for high throughput screening of compounds using frontal chromatography in combination with mass spectrometry. SYNSORB is a Canadian-based pharmaceutical company dedicated to drug development and manufacturing. The Company's two Phase III products have been granted "Fast Track" designation by the FDA and are both based on SYNSORB's proprietary carbohydrate chemistry platform technology. SYNSORB Pk(R) is designed to prevent the progression to Hemolytic Uremic Syndrome (HUS) in children who have contracted verotoxigenic E. coli (VTEC) infections, including E. coli O157:H7. SYNSORB Cd(R) is a potential treatment for recurrent C. difficile antibiotic associated diarrhea (CDAD), a common hospital acquired infection. SYNSORB has built a cGMP-compliant manufacturing facility that has the capacity to meet or exceed the expected global demand for the Company's products. A pipeline of future products is accessible through SYNSORB's carbohybrid program. Jim